King's International visiting fellowships in movement disorders and Neuro-rehabilitation
Dr. Merrie, a consultant in neurorehabilitation at EMC Hospitals in Jakarta, completed her fellowship in Movement Disorders and Parkinson's at King's College Hospital london-Dubai under the supervision of Dr. Vinod Metta, the program director.
She praised the entire training program, noting her experience managing not only advanced Parkinson's patients but also complicated movement disorders. Dr. Merrie expressed her gratitude for the opportunity to witness rare neurological conditions such as corticobasal degeneration, ocular apraxia, and alien limb syndrome—diseases she had only encountered in textbooks.
Additionally, she gained hands-on experience treating patients with dystonia and spasticity through EMG-guided botulinum injections and managing elevated intracranial pressure, all under the mentorship of Dr. Metta and Professor Ray Chaudhuri.
Mr. Mohammed, a neuro-physiotherapist, also participated in the customized Parkinson's neurorehabilitation training program under Dr. Metta's supervision. He was thrilled to share his experiences, particularly how the Parkinson's Centre of Excellence effectively manages advanced Parkinson's cases across diverse races, ages, and stages with a dedicated team of neurophysiotherapists, speech and language therapists, and occupational therapists. He was impressed by the outcomes achieved and noted that this fellowship training provided him with invaluable experience in dealing with complex Parkinson's and movement disorder cases in Jakarta.
Both Dr. Merrie and Mr. Mohammed expressed their gratitude to the management of EMC Hospitals—Pak Jusup, Dr. Juni, Dr. Metta, and Dr. Sedjaya—for nominating them for this prestigious Indonesian overseas training program, as well as to the management team at King's Dubai, including Ms. Kimberley Pierce and Ms. Norafiz Gee, for their support.
They especially thanked the program directors, Dr. Vinod Metta and Professor Ray Chaudhuri, along with all mentors, including Dr. Guy Chung-Faye, Dr. George Kapsas, Dr. Nicandro, and Dr. John.
Dr. Vinod Metta, the Program Director, remarked that the Parkinson's Centre of Excellence at King's Dubai offers exceptional visiting training fellowships. These programs provide neurology residents, junior neurologists, neuro-rehabilitation consultants, and neuro-physiotherapists with comprehensive, hands-on training to manage a range of movement disorders and Parkinson's disease while gaining expertise in neuro-physiology, neuro-radiology, and neuro-spine. He expressed his satisfaction in receiving positive feedback from the first group of visiting fellows.
King's Parkinson's Centre of Excellence
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
05-08-2025
- Al Etihad
Japan firm seeks approval for stem cell treatment for Parkinson's
TOKYO (AFP) Japanese drugmaker Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The company applied to Japanese regulators for manufacturing and marketing authorisation aimed at the treatment of patients with avanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells -- which have the potential to develop into any cell in the body -- was safe and successful in improving symptoms. The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation says. iPS cells are created by stimulating mature, already specialised, cells back into a juvenile state -- basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Gulf Today
10-07-2025
- Gulf Today
A brave calling
The heroes of Israel's war on Gaza are the doctors, nurses, and ambulance drivers who are being killed while saving the lives of others. If ever there were a group of people deserving of the Nobel Peace Prize, it is without a doubt Gaza's healthcare practitioners at all levels. Last Sunday, an Israeli strike on Palestinians sheltering in tents in southern Gaza killed at least eight people, including Drx Mousa Khafaja who was as an obstetrics and gynaecology consultant at Nasser Hospital in southern Gaza. He and family members joined the dozens of Gaza's healthcare professionals to be slain 'at home' in tents because their built homes have been demolished. The most recent internationally known physician to be killed was cardiac surgeon Marwan al-Sultan who was director of the Indonesian Hospital in Jabalya. Colleagues argue he was deliberately targeted because he had become the voice of Gaza's healthcare community to the outside world. 'The Washington Post' reported that he related to its reporters harrowing accounts of how Israel reduced the Gaza health service to a shambles. Due to the high flow of casualties entering the Indonesian hospital, he rarely left his post, and he feared being killed if he did, 'The Post' said. 'The Post' cited Hadiki Habib, head of the Indonesian aid agency that helped finance the Indonesian hospital, who said Dr Sultan had become ''a symbol' of the resilience of Gaza's embattled people.' He was the 70th health worker to be killed since March 18th when Israel broke the two- month ceasefire and resumed its onslaught on Gaza. The killing for Dr. Sultan 'is a catastrophic loss to Gaza and the entire medical community and will have a devastating impact on Gaza's healthcare system,' Healthcare Workers Watch (HWW) director Muath Alser told 'The Guardian.' 'This is part of a much longer and systematic atrocious targeting of healthcare workers sanctioned by impunity. This is a tragic loss of life, but also an obliteration of [doctors'] decades of lifesaving medical expertise and care at a time when the situation facing Palestinian civilians is unfathomably catastrophic,' he added. 'He cannot be replaced,' stated Dr Mohammed Abu Selmia, director of Gaza City's Al-Shifa hospital, which was the main medical facility in the strip until Israel attacked it early in the war. 'He was a prominent scholar, and one of the two remaining cardiologists left in Gaza. Thousands of heart patients will suffer as a result of his killing. His only fault was that he was a doctor. We have no option but to be steadfast, but the sense of loss is devastating,' he also told 'The Guardian.' Among the healthcare providers killed since the ceasefire ended were three other head doctors, the chief nurses of the Indonesian hospital and al-Nasser children's hospital, a senior midwife, a senior radiology technician and dozens pf medical graduates and trainee nurses,' 'The Guardian' reported. Since the Gaza war was launched by Israel, more than 1,580 healthcare workers have been killed and as many as 300 have been detained by Israel, among whom is the director of the Kamal Adwan hospital Dr Hussam Abu Safiya. He has been held since December 2024. Orthopaedic surgeon Dr Adnan al-Bursh, who was working in al-Awda hospital, was arrested during a raid and died in custody in April 2024. The family told 'Al-Jazeera' he was tortured to death. The 4th Geneva Convention prohibits attacks on hospitals, clinics, ambulances, and medical staff. Violating these prohibitions can be treated as war crimes. While under customary international law, 'medical units lose protection if they are being used, outside their humanitarian function, to commit acts harmful to the enemy,' the International Committee of the Red Cross states. Although no evidence has been provided that Gaza's medical units and staff are acting 'outside their humanitarian function,' Israel has claimed, without proof, that Hamas has established command centres in hospitals and fighters are sheltering there. Israel has breached the Geneva Convention by systematically targeting Gaza's entire healthcare system by striking most of Gaza's facilities, slaying doctors, nurses, and ambulance drivers, and blocking the entry of critical medical supplies and fuel for power and ambulances. As hospitals are overwhelmed by the wounded and sick, patients have been treated while lying on corridor floors in their own blood, risking infection. Medicines and bandages are rationed. Due to Israel's blockade, water and food are in short supply for patients and medical staff. 'Nearly all public hospitals in Gaza are down or gutted by months of hostilities and restrictions on the entry of critical medicine, supplies and equipment,' the International Committee of the Red Cross said last week. 'The few medical facilities that continue to function – including the Red Cross Field Hospital – are overwhelmed and running dangerously low on essential supplies, including fuel, and even body bags.' Censorship over Israel's actions continues to reign in Western media. The latest scandal involved the film, 'Doctors Under Attack,' commissioned by the BBC and produced by Basement Films. On June 20, the BBC – which is a government-funded public broadcaster – announced it had would not air the film. 'We have come to the conclusion that broadcasting this material risked creating a perception of partiality that would not meet the high standards that the public rightly expect of the BBC,' the corporation said in a statement. However, the BBC did not define how its impartiality could be put in doubt. Despite the BBC's refusal to carry the film, Britain's independent Channel 4 broadcast it in the UK while Zeteo – founded by progressive US-UK broadcaster Mehdi Hasan – showed it internationally. The documentary, produced by Oscar-nominated, Emmy award and Peabody award-winning filmmakers, describes the challenges faced by Gaza's doctors during Israeli bombardments. The film is not apolitical. Interviewees express opinions held by the overall population. Despite Israel's brutal retributive onslaught on Gaza, several doctors expressed support for Hamas and the Oct.7, 2023, raid when Hamas killed 1,200 and abducted 250, according to Israel. The truth can be controversial as well as informative. Another BBC documentary, 'How to Survive a Warzone,' was shown in November but was promptly dropped following pressure from pro-Israel groups and other UK broadcasters who branded the film 'Hamas propaganda.' No one complains about or censors 'Israeli propaganda.' Photo: TNS
Arabian Post
05-07-2025
- Arabian Post
Parkinson's Study Revives Hopes of Neuronal Recovery
A targeted drug therapy has shown potential to reverse cellular damage in Parkinson's disease by regenerating critical brain structures and restoring neuron function, according to new findings from a leading neuroscience research team. Scientists at Stanford University have demonstrated that suppressing the hyperactivity of a specific enzyme, LRRK2, with a compound called MLi-2 can prompt substantial recovery of dopaminergic signalling in a genetically engineered mouse model of Parkinson's. The treatment not only halted further degeneration but appeared to reverse structural impairments in the affected brain cells, marking a significant shift in understanding how Parkinson's progression might be modified at a cellular level. Parkinson's, a neurodegenerative condition marked by tremors, rigidity, and impaired movement, is primarily caused by the death of dopamine-producing neurons in the brain's substantia nigra. For decades, treatments have largely focused on symptom management rather than tackling the root causes of cellular dysfunction. The Stanford findings now suggest that correcting underlying molecular defects could pave the way for regenerative strategies. ADVERTISEMENT The breakthrough centres on the LRRK2 enzyme, mutations in which are among the most common genetic causes of Parkinson's. Overactive LRRK2 has been linked to damage of cellular structures called primary cilia — antenna-like projections that play a vital role in neuron communication and survival. The research team found that neurons in the striatum of the brain — a key region involved in motor control — lacked these cilia in the Parkinson's model mice. Using the LRRK2-inhibiting compound MLi-2, the team observed a significant regeneration of these lost cilia after three months of treatment. Dopamine signals began to function normally again in many of the affected neurons. The mice showed molecular signs of cellular recovery, with restored receptor localisation and improved intercellular communication. Importantly, the drug was administered after symptoms had started to appear, indicating that early-stage intervention could potentially reverse some aspects of the disease. Further investigations revealed that the repaired cilia helped restore the sonic hedgehog signalling pathway, which is essential for neuron protection and maintenance. In Parkinson's, reduced Shh signalling due to cilia loss contributes to further deterioration of neurons. Restoring this pathway through cilia regrowth suggests a dual benefit: halting ongoing degeneration and triggering repair mechanisms. Although the research was conducted on genetically modified mice, the implications for human forms of Parkinson's could be significant. LRRK2 mutations account for a relatively small percentage of all Parkinson's cases, but the pathway affected by this mutation may play a broader role in other forms of the disease, including idiopathic Parkinson's with unknown genetic causes. The MLi-2 compound itself is a highly selective, brain-penetrant molecule designed to inhibit LRRK2 activity without causing off-target effects. Previous efforts to target LRRK2 were hindered by concerns over safety and unintended consequences in other organs where the enzyme is also active. However, the current study found no major toxic effects over the duration of the experiment, opening the door for cautious optimism about its translational potential. ADVERTISEMENT Neuroscientists have long been searching for ways to go beyond dopamine replacement therapies, which offer temporary relief but do not prevent neuron loss. Deep brain stimulation and other invasive procedures are used in advanced cases but are not curative. A pharmacological approach that addresses root biological causes has remained elusive. The discovery that cellular antennae can regrow and restore critical signalling functions represents a conceptual leap in the field. Experts have noted that early intervention will be key. While the drug showed promise after symptoms appeared, the degree of neuronal recovery is likely to depend on how much degeneration has already taken place. Identifying Parkinson's earlier in its course, perhaps through biomarker detection, may significantly enhance the efficacy of such treatments. Further preclinical studies and safety evaluations are expected before MLi-2 or similar compounds move into human trials. Nonetheless, the research has sparked considerable interest among those exploring disease-modifying treatments. If replicated and expanded, the findings could contribute to a paradigm shift in the management of neurodegenerative conditions more broadly. The concept of regrowing cilia to restore function in damaged neurons could also have implications for other central nervous system disorders involving disrupted cell signalling. Beyond Parkinson's, researchers are already examining cilia dysfunction in conditions such as Alzheimer's and Huntington's disease.
